Biochemical and immunological characterization of an ETEC CFA/I adhesin cholera toxin B subunit chimera. 2020

Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States of America.

Surface-expressed colonization factors and their subunits are promising candidates for inclusion into a multivalent vaccine targeting enterotoxigenic Escherichia coli (ETEC), a leading cause of acute bacterial diarrhea in developing regions. However, soluble antigens are often poorly immunogenic in the absence of an adjuvant. We show here that the serum immune response to CfaE, the adhesin of the ETEC colonization factor CFA/I, can be enhanced in BALB/c mice by immunization with a chimeric antigen containing CfaE and pentameric cholera toxin B subunit (CTB) of cholera toxin from Vibrio cholerae. We constructed this antigen by replacing the coding sequence for the A1 domain of the cholera toxin A subunit (CTA) with the sequence of donor strand complemented CfaE (dscCfaE) within the cholera toxin operon, resulting in a dscCfaE-CTA2 fusion. After expression, via non-covalent interactions between CTA2 and CTB, the fusion and CTB polypeptides assemble into a complex containing a single dscCfaE-CTA2 protein bound to pentameric CTB (dscCfaE-CTA2/CTB). This holotoxin-like chimera retained the GM1 ganglioside binding activity of CTB, as well as the ability of CfaE to mediate the agglutination of bovine red blood cells when adsorbed to polystyrene beads. When administered intranasally to mice, the presence of CTB in the chimera significantly increased the serum immune response to CfaE compared to dscCfaE alone, stimulating a response similar to that obtained with a matched admixture of dscCfaE and CTB. However, by the orogastric route, immunization with the chimera elicited a superior functional immune response compared to an equivalent admixture of dscCfaE and CTB, supporting further investigation of the chimera as an ETEC vaccine candidate.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002772 Cholera Toxin An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells. Cholera Toxin A,Cholera Toxin B,Cholera Toxin Protomer A,Cholera Toxin Protomer B,Cholera Toxin Subunit A,Cholera Toxin Subunit B,Choleragen,Choleragenoid,Cholera Enterotoxin CT,Cholera Exotoxin,Cholera Toxin A Subunit,Cholera Toxin B Subunit,Procholeragenoid,Enterotoxin CT, Cholera,Exotoxin, Cholera,Toxin A, Cholera,Toxin B, Cholera,Toxin, Cholera
D005260 Female Females
D000071497 Immunogenicity, Vaccine The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses. It is typically measured in vaccinated individuals in observational studies setting. Antigenicity, Vaccine,Vaccine Antigenicity,Vaccine Immunogenicity
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D054307 Enterotoxigenic Escherichia coli Strains of ESCHERICHIA COLI that produce or contain at least one member of either heat-labile or heat-stable ENTEROTOXINS. The organisms colonize the mucosal surface of the small intestine and elaborate their enterotoxins causing DIARRHEA. They are mainly associated with tropical and developing countries and affect susceptible travelers to those places. E coli, Enterotoxigenic,ETEC,Escherichia coli, Enterotoxigenic,Enterotoxigenic E. coli

Related Publications

Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
November 1993, Gene,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
May 2006, Biophysical journal,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
December 2023, Pharmaceutical research,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
November 1994, Proceedings of the National Academy of Sciences of the United States of America,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
March 2023, Scientific reports,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
January 1977, Biochemical and biophysical research communications,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
November 1992, Biochemical Society transactions,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
December 1998, FEMS microbiology letters,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
November 1991, Vaccine,
Michael G Jobling, and Steven T Poole, and Fatima Rasulova-Lewis, and Aisling O'Dowd, and Annette L McVeigh, and Amit Balakrishnan, and Stephanie A Sincock, and Michael G Prouty, and Randall K Holmes, and Stephen J Savarino
September 2017, International immunopharmacology,
Copied contents to your clipboard!